Synonym
Dantrolene sodium salt; F 44; F44; F-44
IUPAC/Chemical Name
1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione, monosodium salt
InChi Key
KSRLIXGNPXAZHD-HAZZGOGXSA-M
InChi Code
InChI=1S/C14H10N4O5.Na/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22;/h1-7H,8H2,(H,16,19,20);/q;+1/p-1/b15-7+;
SMILES Code
O=[N+]([O-])C1=CC=C(C2=CC=C(/C=N/N3CC([N-]C3=O)=O)O2)C=C1.[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
336.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Kobayashi, S., Yano, M., Suetomi, T., et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 53(21), 1993-2005 (2009).
2. Oo, Y.W., Gomez-Hurtado, N., Walweel, K., et al. Essential role of calmodulin in RyR inhibition by dantrolene. Mol. Pharmacol. 88(1), 57-63 (2015).
3. Kotsias, B.A., and Muchnik, S. Reversible effect of dantrolene sodium on twitch tension of rat skeletal muscle. Arch. Neurol. 35(4), 234-236 (1978).
4. Nelson, T.E., and Flewellen, E.H. Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia. Anesthesiology 50(2), 118-122 (1979).
